How to use monoclonal antibody-based therapy in ALL
EJC Paediatric Oncology,
Год журнала:
2025,
Номер
unknown, С. 100214 - 100214
Опубликована: Янв. 1, 2025
Язык: Английский
An evaluation of odronextamab for the treatment of multiple subtypes of relapsed/refractory B-cell non-hodgkin lymphoma
Expert Opinion on Biological Therapy,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 19, 2025
Patients
with
relapsed/refractory
B-cell
non-Hodgkin
lymphoma
(B-NHL)
have
a
poor
median
survival
rate
when
treated
traditional
salvage
therapies.
Bispecific
antibodies
(BsAbs)
are
an
emerging
class
of
'off-the-shelf'
immunotherapies
that
show
promising
efficacy
in
this
population.
Odronextamab
is
CD20×CD3
targeting
bispecific
antibody
being
investigated
multiple
subtypes
B-NHL.
This
article
describes
the
development
odronextamab
from
pre-clinical
work
through
to
ongoing
clinical
trials
The
structure,
safety,
and
administration
discussed.
Studies
were
selected
for
inclusion
by
performing
search
PubMed,
EMBASE,
Cochrane
Library
relevant
conference
abstracts
2014
2024.
clinicaltrials.gov
website
reference
lists
included
studies
also
reviewed.
has
demonstrated
manageable
safety
low
rates
immune
effector
cell-associated
neurotoxicity
syndrome
;(ICANS)
high
response
rare
aggressive
B-NHL
particularly
noteworthy.
High
severe
infections
remain
challenge
BsAbs,
further
prophylactic
efforts
required
reduce
risk.
Clinical
combination
therapies
improve
utility
BsAb
across
wider
range
settings
Язык: Английский
Disulfidptosis: A Novel Prognostic Criterion and Potential Treatment Strategy for Diffuse Large B-Cell Lymphoma (DLBCL)
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(13), С. 7156 - 7156
Опубликована: Июнь 28, 2024
Diffuse
Large
B-cell
Lymphoma
(DLBCL),
with
its
intrinsic
genetic
and
epigenetic
heterogeneity,
exhibits
significantly
variable
clinical
outcomes
among
patients
treated
the
current
standard
regimen.
Disulfidptosis,
a
novel
form
of
regulatory
cell
death
triggered
by
disulfide
stress,
is
characterized
collapse
cytoskeleton
proteins
F-actin
due
to
intracellular
accumulation
disulfides.
We
investigated
expression
variations
disulfidptosis-related
genes
(DRGs)
in
DLBCL
using
two
publicly
available
gene
datasets.
The
initial
analysis
DRGs
(GSE12453)
revealed
differences
patterns
between
various
normal
B
cells
DLBCL.
Subsequent
(GSE31312)
identified
strongly
associated
prognostic
outcomes,
revealing
eight
characteristic
(CAPZB,
DSTN,
GYS1,
IQGAP1,
MYH9,
NDUFA11,
NDUFS1,
OXSM).
Based
on
these
DRGs,
were
stratified
into
three
groups,
indicating
that
(1)
can
predict
prognosis,
(2)
help
identify
therapeutic
candidates.
This
study
underscores
significant
role
biological
processes
within
Assessing
risk
scores
individual
allows
for
more
precise
stratification
prognosis
treatment
strategies
patients,
thereby
enhancing
effectiveness
practice.
Язык: Английский
Safety and Efficacy of Bispecific Antibodies in Adults with Large B-Cell Lymphomas: A Systematic Review of Clinical Trial Data
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(17), С. 9736 - 9736
Опубликована: Сен. 9, 2024
Bispecific
antibodies
(bsAbs)
are
an
emerging
therapy
in
the
treatment
of
large
B-cell
lymphomas
(LBCLs).
There
is
a
gap
research
on
safety
and
efficacy
bsAbs
adults
with
LBCL,
current
focusing
wider
non-Hodgkin’s
lymphoma
population.
To
address
this
gap,
we
conducted
systematic
review
aiming
to
evaluate
outcomes
LBCL.
A
systematized
search
was
PubMed,
EMBASE,
CENTRAL
10
April
2024.
Interventional
clinical
trials
were
eligible
for
inclusion.
Observational
studies,
reviews,
meta-analyses
excluded.
According
Revised
Risk
Bias
Assessment
Tool
Nonrandomized
Studies,
included
studies
largely
high
quality
outcome
reporting,
but
mixed
reporting.
Due
heterogeneity
results
discussed
as
narrative
synthesis.
Nineteen
early
phase
evaluated
final
analysis,
pooled
sample
size
1332
patients.
Nine
investigated
across
monotherapy
(nine
studies)
or
combination
regimes
(10
studies).
The
rates
cytokine
release
syndrome
variable,
any
grade
events
ranging
from
0
72.2%.
Infection
consistently
reporting
(38–60%).
Cytopenias
found
be
common,
particular,
anemia
(4.4–62%),
thrombocytopenia
(3.3–69%),
neutropenia
(4.4–70%).
Immune
effector
cell-associated
neurotoxicity
(ICANS)
≥3
adverse
not
commonly
reported.
Promising
reported,
median
overall
response
95–100%
front-line
36–91%
terms
relapsed/refractory
disease.
demonstrate
that
generally
well-tolerated
effective
BsAbs
appear
have
superior
tolerability,
inferior
CAR
T-cell
therapies
Future
should
focus
evaluating
event
timing
management,
impact
patient’s
life,
burden
healthcare
system,
survival
outcomes.
Язык: Английский
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Cancers,
Год журнала:
2024,
Номер
16(24), С. 4181 - 4181
Опубликована: Дек. 15, 2024
Despite
the
great
advancements
in
treatment
strategies
for
hematological
malignancies
(HMs)
over
years,
their
effective
remains
challenging.
Conventional
are
burdened
with
several
serious
drawbacks
limiting
effectiveness
and
safety.
Improved
understanding
of
tumor
immunobiology
has
provided
novel
anti-cancer
targeting
selected
immune
response
components.
Currently,
immunotherapy
is
counted
as
fourth
pillar
oncological
(together
surgery,
chemo-
radiotherapy)
becoming
standard
regimen,
alone
or
combination
therapy.
Several
categories
immunotherapies
have
been
developed
currently
being
assessed
clinical
trials
blood
cancers,
including
checkpoint
inhibitors,
antigen-targeted
antibodies,
antibody–drug
conjugates,
vaccines,
adoptive
cell
therapies.
However,
monoclonal
antibodies
(mAbs)
derivatives
achieved
most
notable
outcome
so
far.
Since
approval
rituximab
treating
B-cell
malignancies,
availability
mAbs
against
tumor-specific
surface
molecules
use
flourished.
Antibody-based
therapy
become
one
successful
immunotherapeutic
cancer
last
few
decades,
many
already
introduced
into
protocols
some
hematologic
malignancies.
To
further
increase
efficacy
mAbs,
they
can
be
conjugated
to
radioisotopes
cytostatic
drugs,
so-called
conjugates.
Moreover,
growing
recognition
T-cell
immunity’s
role
development,
aimed
at
enhancing
T
activation
inhibiting
mechanisms
that
suppress
function
actively
developed.
This
review
provides
a
comprehensive
overview
current
status
based
on
derivatives,
bispecific
engagers,
approved
various
HMs.
Язык: Английский
Monoclonal Antibody Therapies in Cancer Immunotherapy
Advances in medical diagnosis, treatment, and care (AMDTC) book series,
Год журнала:
2024,
Номер
unknown, С. 419 - 472
Опубликована: Авг. 28, 2024
Monoclonal
antibodies
(mAbs)
can
significantly
improve
patient
outcomes
in
cancer
treatment
while
reducing
related
side
effects,
offering
a
targeted
therapy
alternative
to
traditional
regimens.
This
chapter
describes
the
development,
mechanisms,
and
applications
of
mAb
therapies
as
critical
components
immunotherapy.
The
covers
history
progression
use
mAbs
therapy,
their
multiple
mechanisms—such
immune
checkpoint
inhibitors,
acumen
for
antigens
antibody—drug
conjugates—and
newest
developments
this
area.
Moreover,
reviews
relevant
case
studies
trial
data
compare
impact
these
agents
on
various
malignancies.
concludes
with
summary
current
challenges—developed
resistance,
one
hand—and
toxic
e.g.,
cytokine
release
syndrome
neurotoxicity,
other—and
prospective
avenues
field.
Язык: Английский
The landscape of T-cell engagers for the treatment of follicular lymphoma
OncoImmunology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Окт. 8, 2024
Follicular
lymphoma
(FL),
the
second
most
common
subtype
of
non-Hodgkin
lymphoma,
relies
on
interactions
with
immune
elements
in
tumor
microenvironment,
including
T-follicular
helper
cells
and
follicular
dendritic
cells,
for
its
survival
progression.
Despite
initial
responsiveness
to
chemoimmunotherapy,
FL
is
generally
considered
incurable.
Strategies
improve
immune-mediated
control
could
significantly
benefit
this
population,
particularly
as
it
includes
many
elderly
comorbid
patients.
Immune
cell
engagers,
especially
bispecific
antibodies
(BsAbs),
are
crucial
targeting
by
bridging
effector
thereby
triggering
T-cell
activation
cytotoxic
killing.
CD3
×
CD20
BsAbs
have
shown
promise
clinical
development
B-NHL
patients,
structural
variations
affecting
their
target
affinity
potency.
This
review
summarizes
current
trials
relapsed/refractory
FL,
highlighting
approval
some
agents,
role
first-line
treatment
or
combination
therapies,
toxicity
profiles,
future
therapeutic
approach
compared
other
therapies.
Язык: Английский
Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
Rheumatology and Immunology Research,
Год журнала:
2024,
Номер
5(4), С. 209 - 216
Опубликована: Дек. 1, 2024
Abstract
Autoimmune
diseases
arise
from
immune
system
dysfunction
that
cells
mistakenly
attack
the
body’s
own
tissues,
resulting
in
systemic
disorders
or
localized
lesions
such
as
lupus
erythematosus
(SLE)
and
rheumatoid
arthritis
(RA).
Autoreactive
B
play
a
critical
role
pathogenesis
of
many
autoimmune
cell
depletion
using
anti-CD20
monoclonal
antibody
(mAb)
has
been
shown
to
effectively
mitigate
disease
progression
both
preclinical
clinical
studies.
Recently,
bispecific
(bsAb)
targeting
CD20/CD3
have
demonstrated
substantial
benefits
treatment
various
hematologic
malignancies.
Given
their
similar
cytotoxic
mechanism,
bsAb
therapy
may
offer
significant
improvements
management
diseases,
providing
novel
therapeutic
option
for
patients.
This
concise
review
aims
summarize
recent
findings
on
bsAbs
discuss
potential
treating
diseases.
Язык: Английский